Advancing Regulatory Science FDA discovery that Ad5 vector uses coagulation factor X to block complement proteins has major implications for gene therapy Common wisdom has held that the gene transfer vector adenovirus 5 - X Factor - Document - PDFSEARCH.IO

First Page	Meta Content
	Advancing Regulatory Science FDA discovery that Ad5 vector uses coagulation factor X to block complement proteins has major implications for gene therapy Common wisdom has held that the gene transfer vector adenovirus 5 Add to Reading List Open Document File Size: 181,60 KB Share Result on Facebook Facility Meiji Pharmaceutical University / / MedicalTreatment gene therapy / / Organization Department of Biochemistry / FDA / Division of Cellular / Center for Biologics Evaluation and Research / US Food and Drug Administration / Meiji Pharmaceutical University / Tokyo / office of Cellular / / Person Tissue Therapies / Jeffrey S. Smith / Jie Tian / Gene Therapies / Andrew P. Byrnes / Gina M. Conenello / / Position Corresponding author / / PublishedMedium Nature Medicine / / Technology gene therapy / antibodies / / SocialTag Molecular biology Immune system Applied genetics Viral vector Complement system Coagulation Gene therapy Antibody Vector Biology

Advancing Regulatory Science FDA discovery that Ad5 vector uses coagulation factor X to block complement proteins has major implications for gene therapy Common wisdom has held that the gene transfer vector adenovirus 5 Add to Reading List